Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Sci Rep ; 5: 11433, 2015 Jun 15.
Article in English | MEDLINE | ID: mdl-26073760

ABSTRACT

In this study, we examined the possible mechanisms of trehalose (Tre) in improving copper-stress (Cu-stress) tolerance in rice seedlings. Our findings indicated that pretreatment of rice seedlings with Tre enhanced the endogenous Tre level and significantly mitigated the toxic effects of excessive Cu on photosynthesis- and plant growth-related parameters. The improved tolerance induced by Tre could be attributed to its ability to reduce Cu uptake and decrease Cu-induced oxidative damage by lowering the accumulation of reactive oxygen species (ROS) and malondialdehyde in Cu-stressed plants. Tre counteracted the Cu-induced increase in proline and glutathione content, but significantly improved ascorbic acid content and redox status. The activities of major antioxidant enzymes were largely stimulated by Tre pretreatment in rice plants exposed to excessive Cu. Additionally, increased activities of glyoxalases I and II correlated with reduced levels of methylglyoxal in Tre-pretreated Cu-stressed rice plants. These results indicate that modifying the endogenous Tre content by Tre pretreatment improved Cu tolerance in rice plants by inhibiting Cu uptake and regulating the antioxidant and glyoxalase systems, and thereby demonstrated the important role of Tre in mitigating heavy metal toxicity. Our findings provide a solid foundation for developing metal toxicity-tolerant crops by genetic engineering of Tre biosynthesis.


Subject(s)
Antioxidants/pharmacology , Copper/toxicity , Oryza/drug effects , Seedlings/drug effects , Trehalose/pharmacology , Ascorbic Acid/agonists , Ascorbic Acid/biosynthesis , Biological Transport/drug effects , Glutathione/agonists , Glutathione/biosynthesis , Lactoylglutathione Lyase/biosynthesis , Malondialdehyde/metabolism , Oryza/growth & development , Oryza/metabolism , Oxidation-Reduction , Oxidative Stress , Photosynthesis/drug effects , Proline/agonists , Proline/biosynthesis , Pyruvaldehyde/antagonists & inhibitors , Pyruvaldehyde/metabolism , Reactive Oxygen Species/antagonists & inhibitors , Reactive Oxygen Species/metabolism , Seedlings/growth & development , Seedlings/metabolism , Stress, Physiological , Thiolester Hydrolases/biosynthesis
2.
Blood ; 110(5): 1664-74, 2007 Sep 01.
Article in English | MEDLINE | ID: mdl-17551094

ABSTRACT

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis in many transformed cells; however, not all human tumors respond to TRAIL, potentially limiting its therapeutic utility. Although there is substantial evidence that cytotoxic drugs can augment sensitivity to TRAIL, it has become important to know what kinds of nontoxic drugs can be used together with TRAIL. We thus screened several natural compounds that can overcome resistance to TRAIL and found that a cycloanthranilylproline derivative, Fuligocandin B (FCB), an extract of myxomycete Fuligo candida, exhibited significant synergism with TRAIL. Treatment of the TRAIL-resistant cell line KOB with FCB and TRAIL resulted in apparent apoptosis, which was not induced by either agent alone. FCB increased the production of 15-deoxy-Delta(12,14) prostaglandin J(2) (15d-PGJ(2)), an endogenous PPAR gamma ligand, through activation of cyclooxygenase-2 (COX-2). This unique mechanism highlighted the fact that 15d-PGJ(2) directly enhanced sensitivity to TRAIL by inhibiting multiple antiapoptotic factors. More importantly, similar effects were observed in other leukemia cell lines irrespective of their origin. The enhancement was observed regardless of PPAR gamma expression and was not blocked even by peroxisome proliferator-activated receptor-gamma (PPAR gamma) siRNA. These results indicate that 15d-PGJ(2) sensitizes TRAIL-resistant cells to TRAIL in a PPAR gamma-independent manner and that the use of 15d-PGJ(2) or its inducers, such as FCB, is a new strategy for cancer therapy.


Subject(s)
Apoptosis/drug effects , Leukemia/drug therapy , Proline/analogs & derivatives , Prostaglandin D2/analogs & derivatives , TNF-Related Apoptosis-Inducing Ligand/pharmacology , Cell Line, Transformed , Cyclooxygenase 2/metabolism , Drug Resistance, Neoplasm/drug effects , Drug Screening Assays, Antitumor , Drug Synergism , Enzyme Activation/drug effects , Gene Expression Regulation, Leukemic/drug effects , HL-60 Cells , Humans , Inhibitor of Apoptosis Proteins/antagonists & inhibitors , Inhibitor of Apoptosis Proteins/metabolism , K562 Cells , Leukemia/metabolism , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/metabolism , PPAR gamma/biosynthesis , Proline/agonists , Proline/pharmacology , Proline/therapeutic use , Prostaglandin D2/metabolism , TNF-Related Apoptosis-Inducing Ligand/agonists , TNF-Related Apoptosis-Inducing Ligand/metabolism , TNF-Related Apoptosis-Inducing Ligand/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...